Jagsonpal Pharma to Buy Back 16 Lakh Shares Worth ₹40 Crore at ₹250 Each
Jagsonpal Pharmaceuticals Limited will buy back 16 lakh equity shares at ₹250 each, totaling ₹40 crore. The buyback opens on May 8, 2026, and closes on May 14, 2026. The record date is May 4, 2026.
The buyback represents a significant portion of the company's shares and total value, which could impact share price and liquidity, but it is not a fundamental change in the business operations.
A share buyback is generally viewed positively by the market as it can increase earnings per share and signal management's confidence in the company's valuation.
Jagsonpal Pharmaceuticals Limited announced its intention to buy back up to 16,00,000 fully paid-up equity shares, representing 2.38% of its total paid-up share capital. The buyback will be conducted through the tender offer route at a price of ₹250 per equity share, for an aggregate amount of up to ₹40 crore, excluding transaction costs.
The record date for determining the eligibility of shareholders for the buyback was Monday, May 04, 2026. The buyback opening date is scheduled for Friday, May 08, 2026, and it will close on Thursday, May 14, 2026. The last date for receipt of completed tender forms by the registrar is also May 14, 2026, by 5:00 PM IST. The settlement of bids by the clearing corporation is expected by Thursday, May 21, 2026.
This buyback is being undertaken in accordance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, and is within the statutory limit of 25% of the company's paid-up capital and free reserves. The buyback offer size represents 18.35% of the aggregate of fully paid-up equity share capital and free reserves as per the financial year ended March 31, 2025.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under buyback announcement. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.